Donepezil
- Generic Name
- Donepezil
- Brand Names
- Adlarity, Aricept, Namzaric
- Drug Type
- Small Molecule
- Chemical Formula
- C24H29NO3
- CAS Number
- 120014-06-4
- Unique Ingredient Identifier
- 8SSC91326P
- Background
In 2016, the global burden of dementia was estimated to be 43.8 million, demonstrating a significant increase from a global prevalence of 20.2 million in 1990. Donepezil, also known as Aricept, is a piperidine derivative acetylcholinesterase inhibitor used in the management of the dementia of Alzheimer's Disease, and in some cases, is used to manage other ty...
- Indication
Donepezil, administered orally or via transdermal delivery system, is indicated for the treatment of dementia of the Alzheimer's type. It is also available as an extended-release capsule in combination with memantine for the treatment of moderate-to-severe dementia of the Alzheimer's type in patients previously stabilized on 10mg of donepezil hydrochloride o...
- Associated Conditions
- Alzheimer's Disease (AD), Dementia With Lewy Body Disease, Dementia due to Parkinson's disease, Dementia of the Alzheimer's Type, Vascular Dementia (VaD), Moderate Alzheimer's Type Dementia, Severe Alzheimer's Type Dementia
- Associated Therapies
- -
Treatment of Residual Amblyopia With Donepezil
- First Posted Date
- 2012-04-24
- Last Posted Date
- 2021-06-18
- Lead Sponsor
- Boston Children's Hospital
- Target Recruit Count
- 18
- Registration Number
- NCT01584076
- Locations
- 🇺🇸
Boston Children's Physicians South, Weymouth, Massachusetts, United States
🇺🇸Boston Children's Hospital, Boston, Massachusetts, United States
🇺🇸Boston Children's Hospital at Waltham, Waltham, Massachusetts, United States
Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease
- First Posted Date
- 2012-02-07
- Last Posted Date
- 2014-11-19
- Lead Sponsor
- AbbVie (prior sponsor, Abbott)
- Target Recruit Count
- 438
- Registration Number
- NCT01527916
- Locations
- 🇺🇸
Site Reference ID/Investigator# 82994, Jenkintown, Pennsylvania, United States
🇷🇺Site Reference ID/Investigator# 60946, Novosibirsk, Russian Federation
🇷🇺Site Reference ID/Investigator# 60958, St. Petersburg, Russian Federation
The Effect of Donepezil on Gait and Balance in Parkinson's Disease
- First Posted Date
- 2012-01-30
- Last Posted Date
- 2021-10-05
- Lead Sponsor
- Oregon Health and Science University
- Target Recruit Count
- 21
- Registration Number
- NCT01521117
- Locations
- 🇺🇸
Parkinson's Center of Oregon - Oregon Health and Science University, Portland, Oregon, United States
A Bioequivalence Study Comparing Improved Versus Current Orally Disintegrating E2020 10 mg Tablet in Healthy Japanese Adult Males
- First Posted Date
- 2012-01-10
- Last Posted Date
- 2012-06-27
- Lead Sponsor
- Eisai Co., Ltd.
- Target Recruit Count
- 20
- Registration Number
- NCT01506752
A Bioequivalence Study of Film-coated Tablet and Dry Syrup 1% Form for E2020 in Healthy Japanese Adult Males
- First Posted Date
- 2012-01-10
- Last Posted Date
- 2012-01-10
- Lead Sponsor
- Eisai Co., Ltd.
- Target Recruit Count
- 12
- Registration Number
- NCT01506739
Bioequivalence Study for Donepezil Hydrochloride Tablets 10 mg Under Fed Condition
- First Posted Date
- 2012-01-05
- Last Posted Date
- 2012-01-06
- Lead Sponsor
- Dr. Reddy's Laboratories Limited
- Target Recruit Count
- 25
- Registration Number
- NCT01504516
- Locations
- 🇮🇳
Bioserve Clinical Research Private Limited, Hyderabad, Andhra Pradesh, India
Bioequivalence Study for Donepezil Hydrochloride 10 mg Tablets Under Fasting Condition
- First Posted Date
- 2012-01-05
- Last Posted Date
- 2012-01-06
- Lead Sponsor
- Dr. Reddy's Laboratories Limited
- Target Recruit Count
- 26
- Registration Number
- NCT01504503
- Locations
- 🇮🇳
Bioserve Clinical Research Private Limited, Hyderabad, Andhra Pradesh, India
A Double-blind, Placebo-controlled Trial of Donepezil Adjunctive Treatment for Cognitive Impairment in Schizophrenia
- First Posted Date
- 2011-12-13
- Last Posted Date
- 2011-12-13
- Lead Sponsor
- Central South University
- Target Recruit Count
- 80
- Registration Number
- NCT01490567
- Locations
- 🇨🇳
the Second Xiangya Hospital of Central South University, Changsha, Hunan, China
Gabapentin and Donepezil Combination on Experimental Human Pain Models
- Conditions
- Interventions
- First Posted Date
- 2011-12-05
- Last Posted Date
- 2017-06-12
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 48
- Registration Number
- NCT01485185
- Locations
- 🇬🇧
GSK Investigational Site, Cambridge, United Kingdom
Efficacy, Safety, & Tolerability of AZD3480 Patients With Mild to Moderate Dementia of the Alzheimer's Type (AD)
- First Posted Date
- 2011-11-06
- Last Posted Date
- 2015-06-03
- Lead Sponsor
- Targacept Inc.
- Target Recruit Count
- 386
- Registration Number
- NCT01466088
- Locations
- 🇺🇦
Odessa Regional Psychoneurology Dispensary, Odessa, Ukraine
🇺🇦Dnipropetrovsk Regional Clinical Hospital, Dnipropetrovsk, Ukraine
🇺🇦Central Clinical Hospital Ukrzaliznytsi, Kharkiv, Ukraine
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.